Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 16 points (0.1%) at 16,736 as of Wednesday, Oct. 8, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,225 issues advancing vs. 1,774 declining with 143 unchanged.

The Drugs industry currently sits down 1.4% versus the S&P 500, which is unchanged. Top gainers within the industry include Alexion Pharmaceuticals ( ALXN), up 2.0%, Allergan ( AGN), up 1.0%, Amgen ( AMGN), up 1.2%, Teva Pharmaceutical Industries ( TEVA), up 1.0% and Shire ( SHPG), up 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Arrowhead Research ( ARWR) is one of the companies pushing the Drugs industry lower today. As of noon trading, Arrowhead Research is down $6.63 (-53.0%) to $5.88 on heavy volume. Thus far, 35.3 million shares of Arrowhead Research exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $5.47-$12.52 after having opened the day at $11.92 as compared to the previous trading day's close of $12.51.

Arrowhead Research Corporation, a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. Arrowhead Research has a market cap of $713.7 million and is part of the health care sector. Shares are up 15.3% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Arrowhead Research a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Arrowhead Research as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow. Get the full Arrowhead Research Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, AstraZeneca ( AZN) is down $0.38 (-0.6%) to $68.65 on light volume. Thus far, 583,217 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $68.19-$68.69 after having opened the day at $68.25 as compared to the previous trading day's close of $69.03.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $88.4 billion and is part of the health care sector. Shares are up 16.3% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst that rates AstraZeneca a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Valeant Pharmaceuticals International ( VRX) is down $1.08 (-0.9%) to $124.15 on light volume. Thus far, 864,061 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $123.84-$127.74 after having opened the day at $126.25 as compared to the previous trading day's close of $125.23.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $42.8 billion and is part of the health care sector. Shares are up 6.7% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in stock price during the past year, increase in net income, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Valeant Pharmaceuticals International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null